Cor van der Leest
Overview
Explore the profile of Cor van der Leest including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
667
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Veelen A, Veerman G, Verschueren M, Gulikers J, Steendam C, Brouns A, et al.
Int J Cancer
. 2023 Oct;
154(2):332-342.
PMID: 37840304
Osimertinib is prescribed to patients with metastatic non-small cell lung cancer (NSCLC) and a sensitizing EGFR mutation. Limited data exists on the impact of patient characteristics or osimertinib exposure on...
2.
Brouns A, van Veelen A, Veerman G, Steendam C, Dursun S, van der Leest C, et al.
JTO Clin Res Rep
. 2023 May;
4(5):100513.
PMID: 37168878
Introduction: Bone metastases are frequent in patients with -mutated () NSCLC. Skeletal-related events (SREs) are common in these patients; however, no data on SRE in osimertinib-treated patients are reported. We...
3.
Zwierenga F, van Veggel B, Hendriks L, Hiltermann T, Hiddinga B, Hijmering Kappelle L, et al.
Lung Cancer
. 2022 Jul;
170:133-140.
PMID: 35777160
Introduction: Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose...
4.
Agema B, Veerman G, Steendam C, Lanser D, Preijers T, van der Leest C, et al.
Ther Adv Med Oncol
. 2022 Jun;
14:17588359221103212.
PMID: 35677320
Background: Osimertinib is the cornerstone in the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC). Nonetheless, ±25% of patients experience severe treatment-related toxicities. Currently, it is impossible...
5.
Owusuaa C, van der Leest C, Helfrich G, Heller-Baan R, Loenhout C, Herbrink J, et al.
Palliat Med
. 2022 Mar;
36(5):821-829.
PMID: 35331047
Background: Goals of end-of-life care must be adapted to the needs of patients with chronic obstructive pulmonary disease (COPD) who are in the last phase of life. However, identification of...
6.
Steendam C, Atmodimedjo P, de Jonge E, Paats M, van der Leest C, Oomen-de Hoop E, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-9.
PMID: 35100738
Purpose: To compare the results of plasma cell-free DNA (cfDNA) droplet digital PCR (ddPCR) and next-generation sequencing (NGS) on detection of epidermal growth factor receptor () primary activating mutations and...
7.
Visser S, Koolen S, van Donk N, van Walree N, van der Leest C, Cornelissen R, et al.
Thorax
. 2021 Apr;
76(11):1150-1153.
PMID: 33859051
Patients with advanced non-small-cell lung cancer who are treated with pemetrexed display a wide variation in clinical response and toxicity. In this prospective, multicentre cohort study, we investigated the association...
8.
Johnson M, Zvirbule Z, Laktionov K, Helland A, Cho B, Gutierrez V, et al.
J Thorac Oncol
. 2021 Apr;
16(9):1570-1581.
PMID: 33823285
Introduction: Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting DLL3, an atypical Notch ligand expressed in SCLC tumors. We evaluated the efficacy of Rova-T versus placebo as maintenance therapy in...
9.
Steendam C, Veerman G, Pruis M, Atmodimedjo P, Paats M, van der Leest C, et al.
Cancers (Basel)
. 2020 Nov;
12(11).
PMID: 33138052
Although epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are the preferred treatment for patients with -mutated non-small cell lung cancer (NSCLC), not all patients benefit. We therefore explored the...
10.
Steunenberg B, Beddows T, de Groot H, Ayez N, van der Leest C, Aerts J, et al.
Thorac Cancer
. 2020 Oct;
11(12):3456-3462.
PMID: 33026177
Background: Endosonography is accepted as the initial procedure for mediastinal staging in patients with suspected non-small cell lung cancer (NSCLC). However, the diagnostic value of different staging methods in specific...